Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study in Depression and Associated Painful Physical Symptoms

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Duloxetine

First Posted Date: 2010-02-18

Last Posted Date: 2012-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 527

Registration Number: NCT01070329

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Chemotherapy in Treating Patients With Lung Cancer

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Any platinum-based doublet chemotherapy

First Posted Date: 2010-02-12

Last Posted Date: 2012-08-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1610

Registration Number: NCT01067794

Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: tadalafil

First Posted Date: 2010-02-10

Last Posted Date: 2015-10-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1809

Registration Number: NCT01066845

A Study in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2189265
Drug: Exenatide
Drug: Placebo
Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2010-02-08

Last Posted Date: 2015-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 978

Registration Number: NCT01064687

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico

A Study in Advanced Solid Tumors

Phase 2

Completed

Conditions: Solid Tumor

Interventions: Drug: Cetuximab
Drug: Carboplatin
Drug: 5 - FU

First Posted Date: 2010-02-05

Last Posted Date: 2019-09-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT01063075

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada

and more 4 locations

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Ovarian Cancer
Non Small Cell Lung Cancer
Esophageal Cancer
Cancer of Head and Neck
Prostate Cancer
Gastric Cancer
Colorectal Cancer

Interventions: Drug: LY2523355
Drug: pegfilgrastim

First Posted Date: 2010-02-01

Last Posted Date: 2019-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 103

Registration Number: NCT01059643

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States

A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Pemetrexed
Drug: Cetuximab
Drug: Cisplatin
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B12

First Posted Date: 2010-01-27

Last Posted Date: 2013-09-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT01057589

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

Observational Study in Japanese Type 2 Diabetes Patients

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulins

First Posted Date: 2010-01-26

Last Posted Date: 2010-12-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 677

Registration Number: NCT01055808

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan

A Study of the Neurobiology of Depression

Phase 4

Completed

Conditions: Healthy Participants
Major Depressive Disorder

Interventions: Drug: Duloxetine

First Posted Date: 2010-01-18

Last Posted Date: 2014-10-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT01051466

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study for Patients With Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY2605541
Drug: Insulin glargine

First Posted Date: 2010-01-14

Last Posted Date: 2018-04-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 138

Registration Number: NCT01049412

Locations: 🇮🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy